At a time when innovative pharma sector companies are facing the squeeze with pressure on pricing and high costs of bringing new products to market, they have now received further bad news. The University of York has called for the notional cap on the cost of drugs used by the National Institute for Health and Clinical Excellence (NICE) to be reduced by one-third or even two-thirds when deciding on which drugs to fund. The University is funded by the Medical Research Council and work closely with NICE and the Department of Health, so its recommendations are likely to hold weight.
↧